Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Veracyte has unveiled new data at the ENDO 2024 conference showcasing the potential of their Afirma GRID tool in identifying aggressive thyroid tumors. The research suggests that molecular signatures can aid in distinguishing between non-aggressive and aggressive thyroid cancers, thus aiding personalized treatment plans. Key findings from three studies were presented. One study highlighted the high negative predictive value of certain molecular signatures in ruling out significant tumor invasion in over 50% of cases. Another study identified cancer-associated fibroblasts linked to aggressive tumor behavior. A third study detailed the variability of PSMA expression in aggressive thyroid nodules. These insights reinforce Veracyte's commitment to advancing thyroid cancer diagnostics.
Veracyte (Nasdaq: VCYT) announced that data from three studies using the Afirma GRID tool will be presented at ENDO 2024, scheduled for June 1-4 in Boston. These studies aim to provide new molecular insights into thyroid tumors, potentially personalizing treatment further. Key presentations include research on mRNA expression in thyroid tumors, PSMA expression in thyroid nodules, and the correlation of cancer-associated fibroblasts with aggressive thyroid cancer behavior. These findings could help clinicians offer individualized care based on molecular characteristics of patients' tumors.
Veracyte (Nasdaq: VCYT), a prominent cancer diagnostics firm, announced its participation in two upcoming investor conferences. The first is the Leerink Partners 2024 Healthcare Crossroads Conference in Austin, TX, where Veracyte will host a fireside chat on May 29th at 12:20 p.m. ET. The second is the William Blair 44th Annual Growth Stock Conference in Chicago, IL, with Veracyte presenting on June 4th at 5:40 p.m. ET. Live audio webcasts of these events will be available on Veracyte's investor relations website, with replays accessible following the live broadcasts.
Veracyte, Inc. (Nasdaq: VCYT) reported first quarter 2024 financial results, achieving $96.8 million in total revenue, a 17% increase from the previous year. The company experienced a 25% growth in testing revenue and expanded its clinical evidence for Decipher Prostate and Afirma tests. Veracyte acquired C2i Genomics to develop an MRD test, received Medicare coverage for Afirma TERT promoter gene mutation test, and secured a contract with a major U.S. commercial payer. The company improved net loss, raised full-year 2024 revenue guidance to $402-$410 million, and expects $236-$240 million in cash, cash equivalents, and short-term investments by year-end.
Veracyte, Inc. presented data from 14 studies at AUA 2024 showing the effectiveness of Decipher Prostate and Decipher Bladder Genomic Classifiers in providing better prognostic information for patients with prostate and bladder cancer. The research-use-only Decipher GRID tool is also aiding in advancing scientific understanding of these diseases. The studies presented reinforce Veracyte's commitment to evidence-based tests and clinical utility. The Decipher Prostate test has shown the ability to better inform prostate cancer treatment, while the Decipher Bladder test is proving useful in predicting outcomes for bladder cancer patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.